EC Approves Gilead's Viread for HIV-1 Infection in Children, Adolescents

Gilead Sciences, Inc. (Nasdaq: GILD ) today announced that the European Commission has granted marketing authorization for two new indications for once-daily Viread^® (tenofovir disoproxil fumarate). The first new indication permits the use of Viread in combination with other antiretroviral agents for the treatment of HIV-1 infected pediatric patients aged 2 to less